Skip to content

RxB

Active
Private limited company·Activiteiten van medisch specialisten· 3 yrs active
Gemeentestraat 229 ·3010 Leuven, Belgium
KBO/BCE: BE 0804.142.074
Watch Print / PDF
Age3 yrs

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of RxB is 0.2% (very low). The 2025 annual accounts show equity of €271k and a net result of €128k. Equity is growing by ~85.9% per year across the filed fiscal years. Its solvency ranks better than 82% of 2217 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 3 annual accounts.

Signals

3 signals · with evidence
Strong solvency vs sector
Solvency is in the sector's strongest quartile: better than 82% of 2217 peers (2025). A comfortable equity buffer.
View the sector comparison
Consistently profitable
Positive net result in the two most recent financial years (2024 and 2025).
View the result trend
Growing equity
Equity grew over 2023-2025. Profits are largely retained rather than distributed.
View the equity trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Filing behaviour

From the deposit records, complete market-wide
Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 06-05-2026, 86 days ahead of the deadline. This speaks to administrative punctuality and says nothing about the financial position.
The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today.
How we compute the deadline
The year end is derived from 3 filed financial years, each closing on 31-12. The statutory deadline is seven months after the close of the financial year (art. 3:10 par. 1 CAC, art. 3:47 par. 7 for ASBL and foundations). Applied to the financial year that closed on 31-12-2025, that is 31-07-2026.
Deadline per financial year
Year closed Due by Filed Variance Reference
31-12-2025 31-07-2026 06-05-2026 86 d early 2026-00103910
31-12-2024 31-07-2025 20-06-2025 41 d early 2025-00157083
31-12-2023 31-07-2024 12-04-2024 110 d early 2024-00061840

Source: the National Bank's deposit records. Those records are complete, including for years whose figures we have not read yet. Filing late covers nearly half the market and is therefore not scored; only not filing, being more than 90 days late and breaking a punctual record carry weight.

Trust signals

2 signals
More than 3 years active
Founded in 2023, past the statistically most fragile first 3 years.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad, and the KBO register records a normal legal situation.

Administrative Flags

No strikeouts found in the KBO publications we processed. That series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.2% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector Young company +Annual accounts: healthy financial profile

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€128k+10.8%
Working capital€283k+146.1%

Annual accounts & ratios

Source: NBB · 2025
Annual accounts filed on 06-05-2026 with the NBB · fiscal year 2025 · micro
€0€50k€100k€150kOperating result 2023: €33k€33kNet result 2023: €26k€26kOperating result 2024: €150k€150kNet result 2024: €116k€116kOperating result 2025: €168k€168kNet result 2025: €128k€128k202320242025
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Equity: growth of ~85.9%/year over 3 fiscal years, indicative, assuming unchanged policy.
€0€200k€400k€600k2026: €393k (€371k - €415k)2027: €515k (€493k - €537k)2028: €637k (€616k - €659k)2023: €26k2024: €142k2025: €271k202320242025202620272028
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2025 · NACE 86, Human health · compared within the same schema type (micro schema)
Metric This company Sector median Position in the sector
Solvency 87.1% 58.2%
better than 82% of 2217 sector peers
Net result €128k €60k
better than 79% of 2215 sector peers
Equity €271k €74k
better than 86% of 2217 sector peers
Gross operating margin €175k €95k
better than 74% of 2217 sector peers
Total assets €311k €186k
better than 72% of 2217 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P82
2023: P62 · n=53462024: P71 · n=65822025: P82 · n=22172023 2025
Improving position over 2023-2025 · n=2217-6582
Net result P79
2023: P39 · n=53452024: P82 · n=65762025: P79 · n=22152023 2025
Improving position over 2023-2025 · n=2215-6576
Equity P86
2023: P27 · n=53482024: P69 · n=65822025: P86 · n=22172023 2025
Improving position over 2023-2025 · n=2217-6582
Gross operating margin P74
2023: P29 · n=53422024: P76 · n=65842025: P74 · n=22172023 2025
Improving position over 2023-2025 · n=2217-6584
Describes the position versus peers, not a forecast.
EBITDA
€174k
+15.5% 23-25
Net profit
€128k
+10.8% 23-25
Cash flow
€134k
+15.1% 23-25
Total assets
€311k
+75.6% 23-25
Equity
€271k
+90.3% 23-25
Working capital
€283k
+146.1% 23-25
Income taxes
€40k
+16.8% 23-25
Debt
€256
-99.3% 23-25
Debt ≤ 1y
€256
-99.3% 23-25
Current ratio
1108.36
+25562.9% 23-25
Quick ratio
1108.36
+25562.9% 23-25
Solvency
87.1%
+8.4% 23-25
Debt / equity
0.00
-99.6% 23-25
ROE
47.4%
-41.8% 23-25
ROA
41.3%
-36.9% 23-25
Interest coverage
2596.23
-9.7% 23-25
Figures by fiscal year
Fiscal year2025
Depositmicro
Revenue-
EBITDA€174k
Net profit€128k
Cash flow€134k
Staff costs-
Income taxes€40k
Dividends-
Total assets€311k
Equity€271k
Debt€256
of which ≤ 1y€256
of which > 1y-
Working capital€283k
Employees (FTE)-
Ratios (computed)
2025
Current ratio1108.36
Quick ratio1108.36
Working capital ratio91.2%
Solvency87.1%
Debt / equity0.00
Long-term debt ratio-
Interest coverage2596.23
Gross margin-
Net margin-
ROA41.3%
ROE47.4%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€311k
Fixed assets 21/28€27k
Tangible fixed assets 22/27€27k
Current assets 29/58€284k
Amounts receivable within one year 40/41€353
Cash & bank 54/58€153k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€311k
Equity 10/15€271k
Contributions / capital 10/11€100
Reserves 13€271k
Provisions & deferred taxes 16€40k
Amounts payable 17/49€256
Amounts payable within one year 42/48€256
Trade debts payable within one year 44€256
Income statement
Gross operating margin 9900€175k
Operating result 9901€168k
Financial charges 65€67
Result before taxes 9903€168k
Income taxes 67/77€40k
Net result for the period 9904€128k
Result to be appropriated 9905€128k
You are seeing the latest fiscal year only. 2 prior years (figures + ratios) are in a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2025 · computed
100 / 100 Excellent
050100
Computed from 5 of the 6 factors this model weighs. The rest cannot be derived from the filed figures, or need a prior year to compare against.

The full score breakdown, per-year score history and the indicative credit limit are in Kantoor S.

See plans →
Computed by Checked from the NBB filing for FY 2025. Indicative, not credit advice.

Structure & network

Locations & real estate

Registered office

from the Crossroads Bank
Cannot be placed on the map

This address could not be matched to a point in the Belgian address register (BOSA BEST). The address below comes straight from the Crossroads Bank.

Gemeentestraat 2293010 Leuven

Establishment units

1 location
RxB
Gemeentestraat 229, 3010 LeuvenActiviteiten van medisch specialisten
since 20232.347.706.143
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area675 m²
Buildings1
Building footprint172 m²
Volume (LiDAR)1,451 m³
Tallest building11.9 m · ±3 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
24482F0127/00V000 Flanders 675 m² 1 · 172 m² 11.9 m · 3 fl.
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Publications

Lifecycle & Insolvency Signals

No insolvency signals in the Belgian State Gazette

Belgian State Gazette · acts

No structured acts for this company yet

That means one of two things: the company has published no company deeds, or its deeds are still queued for reading. The insolvency signals above come from a separate source; the KBO register is the second source and appears as the legal situation on this page.

Analysis

Snowflake analysis

financial profile on 5 axes
Health100Profitability100Solvency100Growth78Stability94
94 / 100

Exceptional profile, strong across almost every axis.

All 5 axes are computed from data Checked has read.

Health 100
Profitability 100
Solvency 100
Growth 78
Stability 94

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Comparable size, same sector

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Praktijken van specialisten86220Activiteiten van medisch specialisten86220
Primary activity highlighted.
Names & trade names
Legal nameNL RxB
Registered office
Gemeentestraat 229
3010 Leuven, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.